Asli S. Sucu

https://assets.montefioreeinstein.org/profiles/images/16076-asli-sucu.jpg

First Name

Asli

Last Name

Sucu

NPI

1477815934

Faculty ID

16076

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

55869

Is Open Scheduling

Off

Kate R. Steinberg

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/05b61a40-891d-11ec-a48a-e9e0c9e20faa.jpg

First Name

Kate

Last Name

Steinberg

NPI

1528488459

Faculty ID

16973

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

141643

Visit Type ID

2542

Is Open Scheduling

On

Luke R. Sponholz

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Luke

Last Name

Sponholz

NPI

1679837579

Faculty ID

18058

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

55833

Is Open Scheduling

Off

Simon D. Spivack

https://assets.montefioreeinstein.org/profiles/images/Spivack_Simon_MD_2x.jpg

First Name

Simon

Last Name

Spivack

NPI

1366438475

Faculty ID

11003

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Focusing diagnostics and therapeutics on those most likely to benefit is a key to successful intervention&nbsp;at both the public health and clinical levels. The translational goal of the Spivack laboratory is to identify individuals at particularly high risk for lung malignancy, and selected non-malignant lung diseases, upon whom to focus smoking/toxin exposure cessation (primary prevention), chemoprevention (secondary prevention), and early disease detection efforts (disease screening, tertiary prevention).</p>
<p>The laboratory is currently exploring individual Gene x Environment signatures as susceptibility markers by exploring quantitative gene (mRNA) expression phenotypes, and the DNA sequence, methylation, microRNA, and other epigenetic features potentially underlying these expression phenotypes, <em>in vitro</em> and in human populations. This is performed in the setting of defined tobacco, diet, and other exposures. There are both mechanistic and translational components to the studies.&nbsp;</p>
<p><br /><strong>Mechanistically</strong>, the role of epigenetic variation in promoter regions in the 5' and 3' regulatory regions of carcinogenesis and oxidant pathway genes is being explored <em>in vitro</em>, using human genomic DNA reporter constructs, and native gene regulation models. High resolution technologies include the realtime quantitation of native mRNA and microRNA by the laboratory's RNA-specific strategy (<em>patented</em>); the&nbsp;tagged-bisulfite genomic sequencing strategy to determine single base resolution CpG methylation status (tBGS, <em>patented</em>);&nbsp;&nbsp;an experimental strategy for assaying microRNA binding to mRNA, for determining the role of miRNA in candidate gene regulation&nbsp;(<em>patented</em>); and evaluation of functional consequences of DNA&nbsp;methylation detail, using a novel patch reporter construct (<em>patented</em>).&nbsp; A new method to engineer methyl-cytosines into the epigenome has recently been developed.</p>
<p>Whole (epi)genome approaches to identify molecular events unique to lung cancer&nbsp;are being completed, which will represent one of the initial cross-platform 'omics level discovery examinations of&nbsp;lung&nbsp;tissues.&nbsp; The execution of each individual discovery platform involves&nbsp;expert local collaborators and cores&nbsp;in (epi)genetics and genomics, and the "integromics" is critically reliant on Einstein strengths in informatics and biostatistical analyses.</p>
<p>&nbsp;</p>
<p><strong>Translationally</strong>, human lung carcinogenesis biomarkers are being established by pairing laser capture microdissected lung with several unique, non-invasively collected surrogate specimens developed in the laboratory. These include mRNA expression signatures from brush-exfoliated buccal mucosa cells, microRNAs detected in exhaled breath condensate representing first reports for a new exhaled airway biomarker class, and exhaled metabolomic signatures. These airway-derived specimens continue to accrue from a sampling (currently n&gt;1000) of a population assembled in a lung cancer case-control context.&nbsp; The specimens are being studied with a view toward developing non-invasive assays in populations.</p>
<p>&nbsp;</p>
<p>The overall aim is to develop informative non-invasive risk profiling, preventive, and early disease detection strategies for the lung in human populations.</p>
<p>&nbsp;</p>
<p>&nbsp;<em>Work is funded by ongoing NIH,</em><em> DoD,&nbsp;and&nbsp;Foundation support.</em></p>
<p>&nbsp;</p>
<p><strong>Clinical Specialties</strong></p>
<ul style="font-size: 1em; color: #333333; padding: 0px; margin: 20px 0px 25px 38px;">
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung nodule evaluation</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung cancer diagnostics and screening</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">interstitial lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">environmental lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">refractory asthma</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">general pulmonary medicine</li>
</ul>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">A researcher and clinician, Dr. Spivack is developing tests for detecting lung cancer at the earliest possible stage&mdash;before it becomes fatal by spreading to other parts of the body. In one of several NIH-funded studies, his laboratory is working on a noninvasive, early-diagnosis test for lung cancer that detects particular genetic elements and chemicals in exhaled breath.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">In addition to general pulmonary medicine, Dr. Spivack&rsquo;s clinical practice focuses on lung nodule and lung cancer diagnosis, diffuse interstitial lung diseases, and environmental lung diseases.</span></p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease.<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;"><strong></strong></span>

Research Focus

Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans.

Elsevier Profile

Selected Publications

<ol>
<li>Zhenqiu Huang, Alex Maslov, Xiao Dong, Shixiang Sun, Moonsook Lee, Chirag Shah, Ali Sadoughi, Aditi Desai, Dhruv Patel, Taha Siddiqui, Jaiminkumar Patel, Miao Shi, Spencer Waldman, Ava Marsh, Yakov Peter, <strong>*Simon D Spivack,</strong> *Jan Vijg. Somatic Mutations At Single Base Resolution in Single Bronchial Progenitor Cells Collected From Human Lung. <em>(Nature Genetics, April 2022, </em><a href="https://www.nature.com/articles/s41588-022-01035-w&quot; target="_blank">https://www.nature.com/articles/s41588-022-01035-w</a&gt;). (*co-senior authors).</li>
<li>Shi M, Han W, Loudig O, Shah CD, Dobkin JB, Keller S, Sadoughi A, Zhu C, Siegel RE, Fernandez MK, DeLaRosa L, Patel D, Desai A, Siddiqui T, Gombar S, Suh Y, Wang T, Hosgood HD, Pradhan K, Ye K, <strong>Spivack SD.</strong> Initial development and testing of an exhaled microRNA detection strategy for lung cancer case-control discrimination. Sci Rep. 2023 Apr 24;13(1):6620. doi: 10.1038/s41598-023-33698-8. PMID: 37095155; PMCID: PMC10126132.</li>
<li>Yoo EJ, Kim JS, Stransky S, <strong>Spivack S,</strong> Sidoli S. Advances in proteomics methods for the analysis of exhaled breath condensate. Mass Spectrom Rev. 2024 Jul-Aug;43(4):713-722. doi: 10.1002/mas.21871. Epub 2023 Dec 27. PMID: 38149478.</li>
<li>Zefi O, Waldman S, Marsh A, Shi MK, Sonbolian Y, Khulan B, Siddiqui T, Desai A, Patel D, Okorozo A, Khader S, Dobkin J, Sadoughi A, Shah C, <strong>*Spivack S,</strong> *Peter Y. Distinctive field effects of smoking and lung cancer case-control status on bronchial basal cell growth and signaling. Respir Res. 2024 Aug 19;25(1):317. doi: 10.1186/s12931-024-02924-w. PMID: 39160511; PMCID: PMC11334309. *(co-senior authors)</li>
<li>Mitchell MI, Ben-Dov IZ, Ye K, Liu C, Shi M, Sadoughi A, Shah C, Siddiqui T, Okorozo A, Gutierrez M, Unawane R, Biamonte L, Parikh K, <strong>Spivack S,</strong> Loudig O. Exhaled breath condensate contains extracellular vesicles (EVs) that carry miRNA cargos of lung tissue origin that can be selectively purified and analyzed. J Extracell Vesicles. 2024 Apr;13(4):e12440. doi: 10.1002/jev2.12440. Erratum in: J Extracell Vesicles. 2024 May;13(5):e12453. doi: 10.1002/jev2.12453. PMID: 38659349; PMCID: PMC11043690.</li>
<li>Khulan B, Ye K, Shi MK, Waldman S, Marsh A, Siddiqui T, Okorozo A, Desai A, Patel D, Dobkin J, Sadoughi A, Shah C, Gera S, Peter Y, Liao W, *Vijg J, *<strong>Spivack SD</strong>. Normal bronchial field basal cells show persistent methylome-wide impact of tobacco smoking, including in known cancer genes. Epigenetics. 2025 Dec;20(1):2466382. doi: 10.1080/15592294.2025.2466382. Epub 2025 Feb 20. PMID: 39980243; PMCID: PMC11849931. *(co-senior authors)</li>
</ol>

EMR ID

4969

Biography

<p>Simon D. Spivack, MD, MPH, is Professor, Medicine, Epidemiology and Genetics at Montefiore Einstein. He is also former Emeritus Chief, Pulmonary Medicine. Clinically, Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease. </p><p>After obtaining his Bachelor of Science in Psychobiology from McGill University in Montreal, Canada in 1980, Dr. Spivack earned his Doctor of Medicine from the State University of New York Upstate Medical University in 1985. He then completed an internship and residency in internal medicine at the University of Massachusetts Medical Center in 1988. Dr. Spivack then earned his Master of Public Health at Harvard University, School of Public Health in 1989. He completed a clinical pulmonary and critical care medicine and lung research fellowship at the University of Vermont in 1992. </p><p>Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans. His work has been published in numerous peer-reviewed journals, articles, chapters and books, and he has given many national/international presentations, organized symposia and visiting professorships. Dr. Spivack is on the Editorial Board for Scientific Reports and is a reviewer for journals such as <em>PLoS Genetics</em>, <em>Genetics in Medicine</em>, <em>Nature Protocols</em>, <em>American Journal of Respiratory &amp; Critical Care Medicine</em>, <em>Carcinogenesis</em>, <em>Cancer Research</em> and others. He holds multiple United States patents. He has been continually funded by the National Institutes of Health (NIH) for research for over 25 years.
</p><p>Dr. Spivack is board certified in internal medicine, pulmonary medicine and critical care medicine. He is a member of the American Thoracic Society (ATS), the American Association for Cancer Research (AACR) and the American Lung Association (ALA). He is a frequent peer-reviewer on various NIH study sections. In the past, Dr. Spivack won the Excellence in Research Award from ALA and the NIH/National Institute of Environmental Health Sciences (NIEHS) Clinical Scientist Development Award.

</p>

Visit Type ID

2542

Is Open Scheduling

On

Zocdoc Link

Sumeet Singh-Tan

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d41fe610-497e-11ec-8149-d1681d4b2362.jpg

First Name

Sumeet

Last Name

Singh-Tan

NPI

1215318001

Faculty ID

16569

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

14316

Is Open Scheduling

Off

Victoria Lynn Shulman

https://assets.montefioreeinstein.org/profiles/images/Shulman_Victoria_L_MD_2x.jpg

First Name

Victoria

Last Name

Shulman

NPI

1487730339

Faculty ID

5542

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

3853

Biography

Victoria Shulman, MD, is an attending physician at the Children&rsquo;s Hospital at Montefiore Einstein and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Dr. Shulman&rsquo;s clinical focus is in pediatric emergency medicine, with a particular area of interest in resident and medical student education. <br /><br />After obtaining her Bachelor of Arts from the City University of New York, Queens College in 1986, Dr. Shulman earned her Doctor of Medicine at Albert Einstein College of Medicine in 1990. She completed her pediatrics internship and residency at Montefiore Einstein in 1994, where she was Chief Resident in her final year. <br /><br />Dr. Shulman&rsquo;s research aligns with her clinical expertise. Her work has been published in the Journal of Adolescent Health and the Journal of Neurology, as well as chapters in scientific books. <br /><br />Dr. Shulman is board certified by the American Board of Pediatrics. In 1994, she received the Leo M. Davidoff Society Certificate of Distinction for the teaching of medical students. In 2023, Dr. Shulman was inducted as a member of the Leo M. Davidoff Society.<br />

Is Open Scheduling

Off

Mark Shlomovich

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/f00957b0-d372-11ed-b9ca-f36b2b5dc5fe.jpg

First Name

Mark

Last Name

Shlomovich

NPI

1790065910

Faculty ID

15549

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Areas

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

29419

Biography

<p>Mark Shlomovich, MD, is Director, Extracorporeal Liver Support and Director, Pediatric Critical Care Transport at Children&rsquo;s Hospital at Montefiore and Assistant Professor, Pediatrics at Montefiore-Einstein. Dr. Shlomovich&rsquo;s clinical focus is on the care of critically ill children with abdominal organ failure, transplantation and post-surgical care. He also focuses on the safe transportation of critically ill children.</p><p>In 2006, Dr. Shlomovich earned his Bachelor of Science in biology from Towson University. He then attended University of Connecticut School of Medicine earning his Doctor of Medicine in 2010. His postgraduate training began at SUNY Downstate Medical Center with a four-year pediatric residency, where he was Chief Pediatric Resident in his final year. He then came to Children's Hospital at Montefiore for a pediatric critical care fellowship, which he completed in 2017.</p><p>Dr. Shlomovich&rsquo;s research interests are in the use of artificial liver support technology, as well as the care of children in liver failure before and after transplantation. In addition, he investigates the safety and efficiency of the transportation of critically ill children. He has shared his research through peer-reviewed journals and abstracts, and is an ad hoc reviewer for BMC Nephrology.</p><p>Dr. Shlomovich is board certified in general pediatrics and pediatric critical care medicine. He is a member of the Society of Critical Care Medicine and the American Academy of Pediatrics.</p>

Is Open Scheduling

Off

Chirag D. Shah

https://assets.montefioreeinstein.org/profiles/images/physphoto/Shah_Chirag_MD_420x504.jpg

First Name

Chirag

Last Name

Shah

NPI

1164629770

Faculty ID

15234

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5732

Visit Type ID

2542

Is Open Scheduling

On

Theresa M. Serra

https://assets.montefioreeinstein.org/profiles/images/Serra_Theresa_MD_2x.jpg

First Name

Theresa

Last Name

Serra

NPI

1609164078

Faculty ID

14280

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric Medicine

Elsevier Profile

EMR ID

55674

Biography

<p class="MsoNormal">Theresa Serra, MD, joined the CHAM hospitalist division in 2014 after working as a pediatric hospitalist at New York Presbyterian/Lower Manhattan Hospital. Her interests include clinical research and medical education. She has conducted an IRB approved retrospective chart review examining readmission rates in pediatric patients diagnosed with osteomyelitis. Dr. Serra is currently developing a medical Spanish curriculum for faculty members in order to improve communication between patients, families and providers. Along with Courtney McNamara, MD, Dr. Serra is a co-leader of a multidisciplinary committee dedicated to standardizing and improving quality of care for patients hospitalized with the diagnosis of failure to thrive. Dr. Serra is also working on an initiative to identify vaccine delinquency in the inpatient setting through the use of SMART reports.</p> <p class="MsoNormal">Dr. Serra is also collaborating with Lindsey Douglas, MD, MSCR, in an IRB approved quality improvement (QI) project to improve transition-of-care communication between hospitalists and primary care providers and to facilitate the establishment of medical homes. Dr. Serra is also a member of a subcommittee that leads monthly journal clubs/case conferences for pediatric hospitalists.</p>

Is Open Scheduling

Off

Amrita K. Seehra

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Amrita

Last Name

Seehra

NPI

1538548060

Faculty ID

17827

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

29409

Is Open Scheduling

Off